Thus, the correction of GSK3β-CUGBP1 signaling in DM1 mouse models recovers not only muscle dysfunction (muscle weakness, myotonia, atrophy and myopathy), but might also reduce CNS pathology. This evidence concerns the gene CELF1 and myotonic dystrophy type 1.